<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369967</url>
  </required_header>
  <id_info>
    <org_study_id>5120008FN</org_study_id>
    <nct_id>NCT00369967</nct_id>
  </id_info>
  <brief_title>Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents</brief_title>
  <official_title>&quot;Quick Start&quot; Initiation of the Contraceptive Vaginal Ring in Adolescents: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that using &quot;quick start&quot; initiation of the contraceptive vaginal ring in
      adolescents seeking birth control will improve compliance compared to traditional start. We
      will conduct a randomized controlled trial comparing &quot;quick start&quot; to traditional start
      initiation of the contraceptive vaginal ring in adolescents seeking birth control. The
      primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes
      include abnormal bleeding, product satisfaction, and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnancy prevention is an important aspect of adolescent healthcare. Adherence to a chosen
      contraception method is essential to its success. Adolescents are notoriously poor at
      complying with oral contraceptives (OCs), with continuation rates at one year as low as 12%
      (1). In those patients who continue their contraceptive method, our best data estimates that
      the average OC user misses three pills per cycle (2). Given the already highly fluctuant
      serum hormone levels in OC users (3), this leaves poorly compliant users at greater risk for
      unintended pregnancy.

      The contraceptive vaginal ring is a reliable method of contraception and may be particularly
      useful in the adolescent population because of its simple monthly dosing schedule (4). It is
      a combined hormonal contraceptive containing etonogestrel (a progesterone) and ethinyl
      estradiol (an estrogen), which are released continuously at low levels. The vaginal ring has
      been shown to have comparable efficacy and tolerability to OCs (5), but does not require
      daily dosing due to its novel drug delivery system. Studies have shown high rates of
      acceptability and satisfaction with vaginal ring usage in adult and adolescent women and a
      high rate of continuation using a traditional start method (6).

      The &quot;quick start&quot; method of initiating use of OCs has been found to improve continuation
      rates and overall method satisfaction compared to traditional start in large studies of adult
      women (7) and also in small studies of adolescents (8) without significantly affecting
      incidence of breakthrough bleeding or patient satisfaction (9). &quot;Quick start&quot; contraceptive
      vaginal ring has been studied in women aged 18-40 years and found to have a more favorable
      bleeding profile than &quot;quick start&quot; Ortho-Tricyclen Lo (10). This decreased incidence of
      altered bleeding may be a more favorable benefit of &quot;quick start&quot; contraceptive vaginal ring
      in the adolescent population as well.

      One of the biggest obstacles to use of the contraceptive vaginal ring in clinical practice is
      having the patient overcome the idea of vaginally inserting the ring, especially in the
      adolescent population (11). It seems logical that initiating the vaginal ring in the office
      via the &quot;quick start&quot; method may improve patient acceptance and comfort with the method, thus
      improving continuation rates in these patients compared to traditional initiation.

      We propose to perform a randomized controlled trial comparing &quot;quick start&quot; to traditional
      start NuvaRing in adolescents. Subjects meeting inclusion criteria will be randomized to
      either start the method in the office immediately or start the method within 5 days of her
      next menstrual period. Subjects will follow up at 3, 6, and 12 months, at which time we will
      assess continuation, bleeding patterns, pregnancy, and patient satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty in subject recruitment
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuation With the Contraceptive Method</measure>
    <time_frame>3 months</time_frame>
    <description>Participants reporting continuation with contraceptive method at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Method Continuation at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Participants reporting continuation of method at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Method Continuation at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Participants reporting continuation with method at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>3,6, and 12 mo</time_frame>
    <description>Number of pregnancies reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Profile</measure>
    <time_frame>3, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Rating of patient satisfaction with method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Contraception Desired</condition>
  <arm_group>
    <arm_group_label>Quick start</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start contraceptive method (NuvaRing) day of enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional start</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start contraceptive method (NuvaRing) after next menses (per package insert)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing</intervention_name>
    <description>Initiation of NuvaRing for contraception</description>
    <arm_group_label>Quick start</arm_group_label>
    <arm_group_label>Traditional start</arm_group_label>
    <other_name>contraceptive vaginal ring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 1) female aged 15 through 21 presenting for contraception; 2) willing
        to use the NuvaRing as their contraceptive method; 3) English-speaking; 4) up to date on
        routine health maintenance screening (pap smear within 3 years of initiation of sexual
        intercourse and Gonorrhea/ Chlamydia testing yearly or with each new partner); and 5) able
        to read and understand the consent form.

        Exclusion Criteria: 1) are pregnant; 2) have a contraindication to hormonal contraception;
        3) are unwilling to use NuvaRing as their contraceptive method; 4) are currently using any
        hormonal contraceptive or have used one within past 2 months; 5) have used emergency
        contraception in the past 7 days; 6) have had unprotected intercourse in the past 10 days;
        7) have untreated Gonorrhea or Chlamydia; or 8) are unable to give informed consent because
        of psychiatric or cognitive problems.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole W Karjane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol. 1999 May;12(2):90-4.</citation>
    <PMID>10326194</PMID>
  </reference>
  <reference>
    <citation>Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol. 1999 Feb;180(2 Pt 2):276-9.</citation>
    <PMID>9988830</PMID>
  </reference>
  <reference>
    <citation>van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005 Sep;72(3):168-74.</citation>
    <PMID>16102549</PMID>
  </reference>
  <reference>
    <citation>Rivera R, Cabral de Mello M, Johnson SL, Chandra-Mouli V. Contraception for adolescents: social, clinical and service-delivery considerations. Int J Gynaecol Obstet. 2001 Nov;75(2):149-63.</citation>
    <PMID>11684110</PMID>
  </reference>
  <reference>
    <citation>Nov√°k A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception. 2003 Mar;67(3):187-94.</citation>
    <PMID>12618252</PMID>
  </reference>
  <reference>
    <citation>Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005 Mar;71(3):176-82.</citation>
    <PMID>15722066</PMID>
  </reference>
  <reference>
    <citation>Westhoff C, Kerns J, Morroni C, Cushman LF, Tiezzi L, Murphy PA. Quick start: novel oral contraceptive initiation method. Contraception. 2002 Sep;66(3):141-5.</citation>
    <PMID>12384200</PMID>
  </reference>
  <reference>
    <citation>Lara-Torre E, Schroeder B. Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills. Contraception. 2002 Aug;66(2):81-5.</citation>
    <PMID>12204779</PMID>
  </reference>
  <reference>
    <citation>Westhoff C, Morroni C, Kerns J, Murphy PA. Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial. Fertil Steril. 2003 Feb;79(2):322-9.</citation>
    <PMID>12568841</PMID>
  </reference>
  <reference>
    <citation>Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol. 2005 Jul;106(1):89-96.</citation>
    <PMID>15994622</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2006</study_first_submitted>
  <study_first_submitted_qc>August 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2006</study_first_posted>
  <results_first_submitted>December 10, 2015</results_first_submitted>
  <results_first_submitted_qc>June 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2016</results_first_posted>
  <last_update_submitted>June 10, 2016</last_update_submitted>
  <last_update_submitted_qc>June 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Contraceptive vaginal ring</keyword>
  <keyword>Quick start</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not planned.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Traditional Start</title>
          <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
        </group>
        <group group_id="P2">
          <title>Quick Start</title>
          <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Traditional Start</title>
          <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
        </group>
        <group group_id="B2">
          <title>Quick Start</title>
          <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" spread="1.7"/>
                    <measurement group_id="B2" value="18" spread="2.1"/>
                    <measurement group_id="B3" value="18" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>all female participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuation With the Contraceptive Method</title>
        <description>Participants reporting continuation with contraceptive method at 3 months</description>
        <time_frame>3 months</time_frame>
        <population>Number using method at 3 months</population>
        <group_list>
          <group group_id="O1">
            <title>Quick Start</title>
            <description>Start method day of enrollment
NuvaRing: Initiation of NuvaRing for contraception</description>
          </group>
          <group group_id="O2">
            <title>Traditional Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception</description>
          </group>
        </group_list>
        <measure>
          <title>Continuation With the Contraceptive Method</title>
          <description>Participants reporting continuation with contraceptive method at 3 months</description>
          <population>Number using method at 3 months</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Method Continuation at 6 Months</title>
        <description>Participants reporting continuation of method at 6 months</description>
        <time_frame>6 months</time_frame>
        <population>Participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Traditional Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
          </group>
          <group group_id="O2">
            <title>Quick Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Method Continuation at 6 Months</title>
          <description>Participants reporting continuation of method at 6 months</description>
          <population>Participants enrolled</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Method Continuation at 12 Months</title>
        <description>Participants reporting continuation with method at 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Quick Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
          </group>
          <group group_id="O2">
            <title>Traditional Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
          </group>
        </group_list>
        <measure>
          <title>Method Continuation at 12 Months</title>
          <description>Participants reporting continuation with method at 12 months</description>
          <population>Participants enrolled</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy</title>
        <description>Number of pregnancies reported</description>
        <time_frame>3,6, and 12 mo</time_frame>
        <population>There were no reported pregnancies during the study period</population>
        <group_list>
          <group group_id="O1">
            <title>Quick Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
          </group>
          <group group_id="O2">
            <title>Traditional Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy</title>
          <description>Number of pregnancies reported</description>
          <population>There were no reported pregnancies during the study period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Profile</title>
        <time_frame>3, 6, and 12 months</time_frame>
        <population>None of the participants returned their menstrual calendars to assess this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Quick Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
          </group>
          <group group_id="O2">
            <title>Traditional Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Profile</title>
          <population>None of the participants returned their menstrual calendars to assess this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Rating of patient satisfaction with method</description>
        <time_frame>3, 6, and 12 months</time_frame>
        <population>None of the participants returned their satisfaction survey</population>
        <group_list>
          <group group_id="O1">
            <title>Quick Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
          </group>
          <group group_id="O2">
            <title>Traditional Start</title>
            <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Rating of patient satisfaction with method</description>
          <population>None of the participants returned their satisfaction survey</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Traditional Start</title>
          <description>NuvaRing: Initiation of NuvaRing for contraception per package insert</description>
        </group>
        <group group_id="E2">
          <title>Quick Start</title>
          <description>NuvaRing: Initiation of NuvaRing for contraception on day of enrollment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicole Karjane</name_or_title>
      <organization>VCUHS</organization>
      <phone>804-828-8614</phone>
      <email>nkarjane@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

